Reported / Citable
Background
Two securities class actions challenged Cassava Sciences, a biotechnology company, for allegedly making false statements about simufilam, an experimental Alzheimer’s disease treatment. The first consolidated action (filed 2021) alleged Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5 by deceiving investors and inflating stock prices. That action’s certified class covered purchasers between September 14, 2020 and October 12, 2023.
A second class action, filed December 2024 by Stephen Crocker and later captioned by lead plaintiffs including Carlos Pérez-Cotapos Ugarte, alleged similar misconduct but for a different period: October 13, 2023 to March 25, 2025—beginning the day after the first action’s class period ended. Defendants moved to consolidate under Federal Rule 42(a), citing the Court’s earlier order that “any other actions…that arise out of the same facts and claims” shall be consolidated. The consolidated action had settled for $31.25 million.
The Court’s Holding
The Magistrate Judge denied Defendants’ motion to consolidate, exercising discretion afforded by Rule 42(a) and Fifth Circuit precedent. Although both cases involved the same defendants and securities fraud claims, the Court identified decisive factors supporting denial: (1) the cases occupied different procedural stages—the consolidated action had settled and was nearing final approval while Ugarte remained at the pleading stage with pending motions to dismiss; (2) the class periods were distinct and non-overlapping; and (3) consolidation would prejudice the settled plaintiffs and jeopardize their agreement.
The Court relied on longstanding Fifth Circuit authority that consolidation is improper when cases are at markedly different stages of preparation, particularly when one has settled. The opinion noted that consolidating a newly filed case into a settled action would delay final resolution in the older case and create “unneeded repetition and confusion.” Judicial economy considerations—normally favoring consolidation—pointed against it here, as consolidation would not promote efficiency but instead derail the existing settlement.
Key Takeaways
- District courts have broad discretion to deny consolidation under Rule 42(a) when cases are at significantly different procedural stages, particularly when one case has settled.
- Overlapping class periods and common legal claims do not mandate consolidation if consolidation would jeopardize a settlement or prejudice settled parties.
- Courts routinely reject consolidation motions filed after a settlement is reached, viewing such motions as attempts to unwind negotiated releases without additional consideration.
- The practical consequence of consolidation—derailing a settlement to force plaintiffs to litigate additional claims—weighs heavily against consolidation, even when claims share a common factual nucleus.
Why It Matters
This ruling clarifies that defendants cannot use consolidation as a backdoor mechanism to expand or unwind settled class action disputes. After the consolidated Cassava case resolved for $31.25 million, Defendants sought to bundle a later-filed action into that settlement, hoping to obtain a broader release covering claims the Ugarte plaintiffs had deliberately excluded from the settlement negotiations. The Court rejected this opportunistic consolidation, protecting settled plaintiffs from having their judgment jeopardized by new litigation and maintaining the sanctity of negotiated settlements in multi-action scenarios.
For securities litigants and defendants managing multiple overlapping class claims, the decision reinforces that the procedural stage and settlement status of existing cases are material factors in consolidation analysis—not merely the existence of common questions of law or fact. Defendants cannot weaponize consolidation rules to undo settled deals, and plaintiffs’ counsel can proceed with confidence that a settled action will not be derailed by subsequent filings covering adjacent periods.